02393 YESTAR HEALTH
- 0.088
- 0.0000.00%
YESTAR HEALTH News
Yestar Healthcare Appoints CFO
yestar health (02393.HK): Qiao Jinrong was appointed as an executive director.
Great Wisdom News on October 15th, yestar health (02393.HK) announced that Mr. Wang Hong has resigned as the company's executive director, CFO, authorized representative, and a member of the investment committee under the board of directors, in order to devote more time to family care, effective from October 15, 2024. Ms. Wang will continue to serve the group in the new role of senior advisor. In addition, Mr. Qiao Jinrong has been appointed as the company's executive director, effective from October 15, 2024.
Express News | Yestar Healthcare - Wang Hong Tendered Resignation as Executive Director, CFO
Express News | Yestar Healthcare Holdings Co Ltd - Qiao Jinrong Appointed as Executive Director
We Believe Yestar Healthcare Holdings' (HKG:2393) Earnings Are A Poor Guide For Its Profitability
YESTAR HEALTH: Interim report 2024
Yestar Health [02393] is now trading at HKD 0.046, a decrease of 11.54%.
As of 10:53, Yestar Health Holdings [02393] reported HK$0.046, down HK$0.006 or 11.54% from the previous closing price of HK$0.052. The turnover was HK$0.0093 million. The highest price today was HK$0.045, and the lowest price was HK$0.045. Based on yesterday's closing price, the 10-day average price is HK$0.05, and the 50-day average price is HK$0.05. The current P / E ratio is -7.27 times, and the 14-day relative strength index is 54.55.
YESTAR HEALTH: INTERIM RESULTS FOR SIX MONTHS ENDED 30 JUNE 2024
Yestar Health (02393.HK) expected significant growth in net profit in the mid-term.
Yestar Health (02393.HK) announced that compared with the unaudited comprehensive net profit of approximately RMB 11.6 million for the first six months ended June 30, 2023, the unaudited comprehensive net profit for the mid-term period during 2024 is expected to increase significantly by no less than RMB 1,050 million. The expected significant increase in the group's mid-term net profit mainly comes from (i) confirming substantial premiums due to the redemption of the preferred notes originally due in 2026 at a discount price, and (ii) reducing financial costs after redeeming the related preferred notes.
Yestar Health (02393) announces profit growth, with expected mid-term comprehensive net profit increase of no less than 1.05 billion yuan.
Yestar Health (02393) announced that the expected net profit for the first half of 2023 is approximately RMB 11.6 million, compared with the same period last year.
Express News | Yestar Healthcare Sees Increase in Hy Unaudited CONSOL Net Profit of Group of Not Less Than RMB1,050 Mln
YESTAR HEALTH: POSITIVE PROFIT ALERT
Yestar Health (02393.HK) plans to hold a board of directors meeting on August 29 to approve the mid-term performance.
Yestar Health (02393.HK) announced on August 14 that the board of directors will hold a meeting on August 29, 2024 (Thursday), to (including) consider and approve the unaudited comprehensive mid-term performance of the company and its subsidiary companies for the six months ending June 30, 2024, as well as declare a mid-term dividend (if any).
Second Arbitration Related to Yestar Healthcare's Trading Firm Acquisition Terminated
Yestar Healthcare Narrows Loss in 2023
YESTAR HEALTH: ANNUAL REPORT 2023
Yestar Healthcare Faces Second Arbitration Related to Trading Firm Acquisition
Superstar Healthcare Holdings (02393): Leung Chun-hung resigns as executive director
Superstar Medical Holdings (02393) announced that Leung Chun-hung undertakes other duties related to his future career and business development...
Superstar Medical Holdings (02393) announced annual results. Losses attributable to shareholders of 13.888 million yuan narrowed 98.6% year-on-year
According to the Zhitong Finance App, Superstar Medical Holdings (02393) announced its annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 2,913 billion yuan (RMB, same below) during the period, an increase of 3.86% over the previous year; losses attributable to shareholders were 13.888 million yuan, a year-on-year decrease of 98.6%; and a basic loss of 0.6 points per share. According to the announcement, demand for the Group's in vitro diagnostic consumables increased in 2023, mainly due to a sharp rise in demand for cardiomyocardial products from patients with diseases caused by COVID-19 in the first quarter of 2023. Receipts from continuing operations in this segment
YESTAR HEALTH: ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Analysis
Price Target
No Data
No Data